Finance

Lists
524715:BOM
Sun Pharmaceutical Industries Ltd
1 760,00 INR
-0,03%
(-0,60) 1D
16-окт., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524715...
Open
1 759,60 INR
High
1 764,40 INR
Low
1 744,85 INR
Mkt. cap
4,22 трлн
Avg. vol.
97,37 миң
Volume
35,68 миң
Dividend
0,91%
Quarterly dividend
4,00 INR
Ex-dividend date
2026-ж., 7-июл.
P/E ratio
34,89
52-wk high
2 047,55 INR
52-wk low
1 583,60 INR
EPS
50,44 INR
Shares outstanding
0,00
No. of employees
47 миң
Open
1 759,60 INR
High
1 764,40 INR
Low
1 744,85 INR
Mkt. cap
4,22 трлн
Avg. vol.
97,37 миң
Volume
35,68 миң
Dividend
0,91%
Quarterly dividend
4,00 INR
Ex-dividend date
2026-ж., 7-июл.
P/E ratio
34,89
52-wk high
2 047,55 INR
52-wk low
1 583,60 INR
EPS
50,44 INR
Shares outstanding
0,00
No. of employees
47 миң
News stories
From web sources and news partners
Profile
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
About Sun Pharmaceutical Industries Ltd
CEO-
Employees47 миң
Founded1983
HeadquartersГорегаон Восток, Мамбай, Индия
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
144,78 млд
155,21 млд
146,12 млд
153,00 млд
Cost of goods sold
29,83 млд
29,45 млд
37,36 млд
29,63 млд
Cost of revenue
29,83 млд
29,45 млд
37,36 млд
29,63 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,65 млд
28,92 млд
30,60 млд
32,27 млд
Operating expense
81,28 млд
85,13 млд
80,66 млд
87,80 млд
Total operating expenses
111,11 млд
114,58 млд
118,02 млд
117,43 млд
Operating income
33,67 млд
40,62 млд
28,10 млд
35,57 млд
Other non operating income
4,70 млд
5,79 млд
-14,29 млд
7,24 млд
EBT including unusual items
41,55 млд
42,07 млд
35,37 млд
40,89 млд
EBT excluding unusual items
41,55 млд
46,97 млд
26,83 млд
42,93 млд
Income tax expense
10,31 млд
8,26 млд
8,28 млд
11,88 млд
Effective tax rate
24,80%
19,63%
23,40%
29,05%
Other operating expenses
46,34 млд
48,89 млд
42,30 млд
48,14 млд
Net income
31,18 млд
33,69 млд
27,14 млд
28,95 млд
Net profit margin
21,54%
21,71%
18,57%
18,92%
Earnings per share
13,00
15,48
11,30
12,71
Interest and investment income
-
-
9,74 млд
-
Interest expense
-998,60 млн
-783,60 млн
-858,90 млн
-996,70 млн
Net interest expenses
-998,60 млн
-783,60 млн
8,89 млд
-996,70 млн
Depreciation and amortization charges
7,30 млд
7,32 млд
7,75 млд
7,39 млд
EBITDA
40,82 млд
46,53 млд
34,86 млд
42,32 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору